Shared and separate functions of polo-like kinases and aurora kinases in cancer
The DOI matches its Crossref record; 228 of the 228 references it cites were found in a registry or an index.
Abstract
Large numbers of inhibitors for polo-like kinases and aurora kinases are currently being evaluated as anticancer drugs. Interest in these drugs is fuelled by the idea that these kinases have unique functions in mitosis. Within the polo-like kinase family, the emphasis for targeted therapies has been on polo-like kinase 1 (PLK1), and in the aurora kinase family drugs have been developed to specifically target aurora kinase A (AURKA; also known as STK6) and/or aurora kinase B (AURKB; also known as STK12). Information on the selectivity of these compounds in vivo is limited, but it is likely that off-target effects within the same kinase families will affect efficacy and toxicity profiles. In addition, it is becoming clear that interplay between polo-like kinases and aurora kinases is much more extensive than initially anticipated, and that both kinase families are important factors in the response to classical chemotherapeutics that damage the genome or the mitotic spindle. In this Review we discuss the implications of these novel insights on the clinical applicability of polo-like kinase and aurora kinase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, some kinases and phosphatases simultaneously hit the same kinesins to tune the balance between phosphorylation and dephosphorylation to modulate activity or spindle targeting [56, 57].”
From Regulatory mechanisms that control mitotic kinesins (2015) · cites this paper as [56]
Citations
Cites
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000 · cited 1×
“Well-known examples of these drugs are those that perturb the formation of the mitotic spindle such as taxanes and vinca alkaloids”
BackgroundEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“This means that their mode of action will be different from inhibitors of the ERBB2 (also known as HER2 or neu receptor) or the breakpoint cluster region (BCR)–ABL1 oncoproteins that directly suppress oncogenic signal”
BackgroundAddiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
The anaphase promoting complex/cyclosome: a machine designed to destroy
Peters, J.-M. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1988 · Cited by 1,315 · cited 1×
“Once proper chromosome alignment is established, cyclin B and securin are degraded by the anaphase-promoting complex/cyclosome bound to CDC20 (APC/C CDC20”
BackgroundTyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281 · cited 1×
“This means that their mode of action will be different from inhibitors of the ERBB2 (also known as HER2 or neu receptor) or the breakpoint cluster region (BCR)–ABL1 oncoproteins that directly suppress oncogenic signal”
BackgroundTumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation
Zhou, H., Kuang, J., Zhong, L., Kuo, W.-L., Gray, J., Sahin, A., Brinkley, B., & Sen, S. (1998) · Nature Genetics · doi:10.1038/2496 · Cited by 1,276
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
Bischoff, J. R. (1998) · The EMBO Journal · doi:10.1093/emboj/17.11.3052 · Cited by 1,216 · cited 1×
“Oncogenic activity Overexpression of aurora kinase A induces oncogenic transformation in immortalized rodent fibroblast”
BackgroundDitchfield, C., Johnson, V. L., Tighe, A., Ellston, R., Haworth, C., Johnson, T., Mortlock, A., Keen, N., & Taylor, S. S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208091 · Cited by 1,194 · cited 1×
“gov/drugdictionary/?CdrID=39762">paclitaxel (also known as Taxol)-induced mitotic arres”
BackgroundHauf, S., Cole, R. W., LaTerra, S., Zimmer, C., Schnapp, G., Walter, R., Heckel, A., van Meel, J., Rieder, C. L., & Peters, J.-M. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200208092 · Cited by 1,155 · cited 1×
“gov/drugdictionary/?CdrID=39762">paclitaxel (also known as Taxol)-induced mitotic arres”
BackgroundA Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017 · cited 1×
“Most recently, tumour cell lines carrying a KRAS-G13D mutation were shown to be hypersensitive to inhibition of PLK1 (Ref”
Background
Cited by
Items 101–200 of 609
Centrosome amplification in tumorigenesis
Anderhub, S. J., Krämer, A., & Maier, B. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.006 · Cited by 85
Kemp, S. R. M., Nagel, R., van Walsum, M., van der Meulen, I. H., van Beusechem, V. W., Braakhuis, B. J. M., & Brakenhoff, R. H. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2539 · Cited by 75
“Food and Drug Administrationapproved mitotic spindle drugs like taxanes and vinca alkaloids (26, 27).”
BackgroundMutant TP53 Posttranslational Modifications: Challenges and Opportunities
Nguyen, T.-A., Menendez, D., Resnick, M. A., & Anderson, C. W. (2014) · Human Mutation · doi:10.1002/humu.22506 · Cited by 69
“Both AURA and AURB are overexpressed in several cancers including breast, colorectal, and prostate [Lens et al., 2010], and many cancers exhibit elevated JNK activity [Sabapathy, 2012].”
BackgroundAURKA regulates JAK2–STAT3 activity in human gastric and esophageal cancers
Katsha, A. M., Arras, J., Soutto, M., Belkhiri, A., & El-Rifai, W. M. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.012 · Cited by 78
“AURKA is a serine/threonine kinase that localizes to spindle poles and ensures its correct assembly in normal cells (Lens et al., 2010).”
BackgroundLatham, J. A., Chosed, R. J., Wang, S., & Dent, S. Y. R. (2011) · Cell · doi:10.1016/j.cell.2011.07.025 · Cited by 70
“Aurora kinase functions are essential for normal chromosome segregation, and overexpression of these enzymes occurs in many types of human cancers (Lampson and Cheeseman, 2011; Lens et al., 2010).”
MiR-210 disturbs mitotic progression through regulating a group of mitosis-related genes
He, J., Wu, J., Xu, N., Xie, W., Li, M., Li, J., Jiang, Y., Yang, B. B., & Zhang, Y. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks995 · Cited by 74
“Plk1 regulates sister chromatid resolution by promoting the removal of cohesins in prophase and facilitating their cleavage by separase (44,45).”
Meyer, R. E., Kim, S., Obeso, D., Straight, P. D., Winey, M., & Dawson, D. (2013) · Science · doi:10.1126/science.1232518 · Cited by 70
Mitotic centromere-associated kinesin (MCAK): a potential cancer drug target
Sanhaji, M., Friel, C. T., Wordeman, L. G., Louwen, F., & Yuan, J. (2011) · Oncotarget · doi:10.18632/oncotarget.416 · Cited by 86
“It localizes to centrosomes and spindle poles and drives centrosome maturation, separation and bipolar spindle assembly [67-69].”
BackgroundKnobloch, T. J., Uhrig, L. K., Pearl, D. K., Casto, B. C., Warner, B. M., Clinton, S. K., Sardo, C. L., Ferguson, J. M., Daly, B. T., Riedl, K. M., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0187 · Cited by 69
Veitch, Z. W. N., Cescon, D. W., Denny, T. A., Yonemoto, L.-M., Fletcher, G. C., Brokx, R. D., Sampson, P. B., Li, S.-W., Pugh, T. J., Bruce, J. P., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0517-3 · Cited by 69
Serpico, A. F., Visconti, R., & Grieco, D. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2567-0 · Cited by 71
Nuclear localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer
Naso, F. D., Boi, D., Ascanelli, C., Pamfil, G., Lindon, C., Paiardini, A., & Guarguaglini, G. (2021) · Oncogene · doi:10.1038/s41388-021-01766-w · Cited by 74
“types of cancer such as neuroblastoma, lymphoma, breast, colorectal, ovarian and prostate cancers [9, 10].”
BackgroundTumour selective targeting of cell cycle kinases for cancer treatment
Aarts, M., Linardopoulos, S., & Turner, N. C. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.012 · Cited by 78
“AURKA is critical for centrosome maturation and proper formation of the mitotic spindle [23].”
BackgroundMethodInfluentialA proteomic approach for the identification of novel lysine methyltransferase substrates
Levy, D., Liu, C. L., Yang, Z., Newman, A. M., Alizadeh, A. A., Utz, P. J., & Gozani, O. (2011) · Epigenetics & Chromatin · doi:10.1186/1756-8935-4-19 · Cited by 67
“Two serine/threonine kinases were discovered: PAK4 regulates cytoskeletal architecture, cell proliferation, and the cell cycle, and is required for embryonic viability [25,26], while PLK1 is involved in regulation of mitosis, including centrosome maturation and spindle assembly [27].”
BackgroundSharma, S., Zeng, J.-Y., Zhuang, C.-M., Zhou, Y.-Q., Yao, H., Hu, X., Zhang, R., & Wang, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1079 · Cited by 66
Moura, D. S., Campillo‐Marcos, I., Vázquez-Cedeira, M., & Lazo, P. A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2746-7 · Cited by 67
“Some like cyclin-dependent kinases [1], polo-like kinases [2], and Aurora kinases [3] control cell cycle progression.”
BackgroundMarkant, S. L., Esparza, L. A., Sun, J., Barton, K. L., McCoig, L. M., Grant, G. A., Crawford, J. R., Levy, M. L., Northcott, P. A., Shih, D. J. H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4258 · Cited by 65
“Each of these serine/threonine kinases plays a distinct role in G2–M phase progression (35).”
BackgroundPLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy
Ruf, S., Heberle, A. M., Langelaar‐Makkinje, M., Gelino, S., Wilkinson, D., Gerbeth, C., Schwarz, J., Holzwarth, B., Warscheid, B., Meisinger, C., et al. (2017) · Autophagy · doi:10.1080/15548627.2016.1263781 · Cited by 69
“PLK1 inhibitors are investigated as antimitotic agents for cancer treatment.(1,6,7) MTOR (mechanistic target of rapamycin) is another serine/threonine protein kinase that promotes cellular growth and is also often targeted in cancer therapy.”
BackgroundAurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review
Gavriilidis, P., Giakoustidis, A. E., & Giakoustidis, D. E. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2295w · Cited by 65
“While inhibition of aurora A leads to arrest in mitosis, in contrast inhibition of aurora B inactivates the checkpoints and leads to chromosome misalignment and failed cytokinesis [31].”
BackgroundPhospho-TCTP as a therapeutic target of dihydroartemisinin for aggressive breast cancer cells
Lucibello, M., Adanti, S., Antelmi, E., Dezi, D., Ciafrè, S., Carcangiu, M. L., Zonfrillo, M., Nicotera, G., Sica, L., de Braud, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2971 · Cited by 63
“PLK1 is a crucial serin/treonin kinase in regulating cell proliferation, whose overexpression has been observed in many tumors, including breast cancer [45].”
BackgroundTargeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives
Vlachostergios, P. J., & Papandreou, C. N. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00006 · Cited by 64
“PLK1 mediates entry into mitosis as well as centrosome maturation, spindle checkpoint activity, activation of the anaphase-promoting complex, and eventual exit from the M-phase with the initiation of cytokinesis (13).”
BackgroundThe Elephant in the Room: The Role of Microtubules in Cancer
Cirillo, L., Gotta, M., & Meraldi, P. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57127-0_5 · Cited by 69
Li, X., Huang, W., Huang, W., Wei, T., Zhu, W., Chen, G., & Zhang, J. (2020) · PubMed · Cited by 76
The potential role of Aurora kinase inhibitors in haematological malignancies
Farag, S. S. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08898.x · Cited by 63
Kasahara, K., Goto, H., Izawa, I., Kiyono, T., Watanabe, N., Elowe, S., Nigg, E. A., & Inagaki, M. (2013) · Nature Communications · doi:10.1038/ncomms2879 · Cited by 64
Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins
Boeckx, C., de Beeck, K. O., Wouters, A., Deschoolmeester, V., Limame, R., Zwaenepoel, K., Specenier, P. M., Pauwels, P., Vermorken, J. B., Peeters, M., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.039 · Cited by 68
“Importantly, high expression of aurora kinases can be found in many malignant tumors [24,65,66].”
Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins
Zheng, N., Wang, Z. P., & Wei, W. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.02.005 · Cited by 70
“Aurora kinases play important roles in mitosis (Carmena and Earnshaw, 2003, Ducat and Zheng, 2004, Fu et al. , 2007, Katayama et al. , 2003, Lens et al. , 2010, Lindqvist et al. , 2009, Ruchaud et al. , 2007).”
BackgroundKIBRA Protein Phosphorylation Is Regulated by Mitotic Kinase Aurora and Protein Phosphatase 1
Xiao, L., Chen, Y., Ji, M. H., Volle, D. J., Lewis, R. E., Tsai, M.-Y., & Dong, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.246850 · Cited by 65
An exploration of pathways involved in lung carcinoid progression using gene expression profiling
Swarts, D. R. A., Neste, L. V., Henfling, M. E. R., Eijkenboom, I., Eijk, P. P., van Velthuysen, M. F., Vink, A., Volante, M., Ylstra, B., Criekinge, W. V., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt271 · Cited by 63
“Alterations of both the MSC and CPC proteins have been reported to cause CIN (24,25) and both up- and downregulation of CPC members, including ABk, may cause this effect (60).”
BackgroundInfluentialTargeting mitosis exit: A brake for cancer cell proliferation
Liu, X., Chen, Y., Li, Y., Petersen, R. B., & Huang, K. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.007 · Cited by 67
Kim, J. H., Shim, J., Ji, M.-J., Jung, Y., Bong, S. M., Jang, Y., Yoon, E.-K., Lee, S.-J., Kim, K. G., Kim, Y. H., et al. (2014) · Nature Communications · doi:10.1038/ncomms5588 · Cited by 59
The G2 checkpoint—a node‐based molecular switch
de Gooijer, M. C., van den Top, A., Bočkaj, I., Beijnen, J. H., Würdinger, T., & van Tellingen, O. (2017) · FEBS Open Bio · doi:10.1002/2211-5463.12206 · Cited by 69
Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications
Shakeel, I., Basheer, N., Hasan, G. M., Afzal, M., & Hassan, M. I. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1818760 · Cited by 58
“Among the members of the PLKs family, mammalian PLK1 is widely investigated, giving its strong association with tumorigenesis [2].”
BackgroundIndependent prognostic implications of RRM2 in lung adenocarcinoma
Ma, C., Luo, H., Cao, J., Gao, C., Fa, X., & Wang, G. (2020) · Journal of Cancer · doi:10.7150/jca.47895 · Cited by 70
“PLK1 is indispensable for finely regulating cell division and maintenance of genomic stability in mitosis, spindle assembly, and DNA damage response [40].”
BackgroundCell Death Signaling and Anticancer Therapy
Galluzzi, L., Vitale, I., Vacchelli, E., & Kroemer, G. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00005 · Cited by 64
“1http://www.clinicaltrials.gov kinase 1 (CHEK1) (Dai and Grant, 2010; Ma et al., 2011), of Pololike kinases (PLKs) (Degenhardt and Lampkin, 2010; Lens et al., 2010), of survivin (Ryan et al., 2009), and of kinesin-related proteins (Huszar et al., 2009), just to mention a few examples (Table…”
BackgroundLee, Y., Wu, W., Ji, W., Chen, J. Y., Cheng, Y., Chiang, M., & Chen, H. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-9 · Cited by 64
“chromosome condensation and interacts with INCENP, survivin, and borealin to form chromosomal passenger complex for chromosome arrangement during cytokinesis [11-14].”
BackgroundThe Role of APAL/ST8SIA6-AS1 lncRNA in PLK1 Activation and Mitotic Catastrophe of Tumor Cells
Luo, M., Li, J., Shen, L., Chu, J., Guo, Q., Liang, G., Wu, W., Chen, J., Chen, R., & Song, E. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz134 · Cited by 63
“Aurora A-mediated activation of PLK1, the central kinase regulating multiple stages of mitosis, is fundamental for PLK1 to exert its oncogenic function in malignant cells (31).”
BackgroundBush, T. L., Payton, M. N., Heller, S., Chung, G., Hanestad, K., Rottman, J. B., Loberg, R. D., Friberg, G. R., Kendall, R. L., Saffran, D. C., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1178 · Cited by 63
“number of reports have shown that Aurora kinase inhibitors can act synergistically with MTAs, such as taxanes or vinca alkaloids, to inhibit the growth of cancer cell lines in vitro (2, 3).”
BackgroundAsteriti, I. A., Giubettini, M., Lavia, P., & Guarguaglini, G. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-131 · Cited by 62
“Novel molecules with Aurora-A-inhibitory activity are being designed in many laboratories, some of which have yielded promising results in pre-clinical studies and are under evaluation in phase I and II clinical trials (see [12] for a recent review).”
BackgroundMethodde Cárcer, G., Wachowicz, P., Martínez-Martínez, S., Oller, J., Méndez‐Barbero, N., Escobar, B., González‐Loyola, A., Takaki, T., Bakkali, A. E., Cámara, J. A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4364 · Cited by 61
Koczor, C. A., Lee, E. K., Torres, R. A., Boyd, A., Vega, J. D., Uppal, K., Yuan, F., Fields, E. J., Samarel, A. M., & Lewis, W. (2013) · Physiological Genomics · doi:10.1152/physiolgenomics.00013.2013 · Cited by 56
“AURKB is a cell cycle-related gene encoding a serine-threonine protein kinase with no known role in DCM or cardiac function (21).”
BackgroundKim, K., Choe, H., Jeong, Y. J., Lee, J. H., & Hong, S. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b01138 · Cited by 56
Aurora A kinase activates YAP signaling in triple-negative breast cancer
Chang, S. H., Yamaguchi, H., Xia, W., Lim, S.-O., Khotskaya, Y. B., Wu, Y., Chang, W.-C., Liu, Q., & Hung, M. (2016) · Oncogene · doi:10.1038/onc.2016.292 · Cited by 60
The expression of AURKA is androgen regulated in castration-resistant prostate cancer
Kivinummi, K. K., Urbanucci, A., Leinonen, K. A., Tammela, T. L. J., Annala, M., Isaacs, W. B., Bova, G. S., Nykter, M., & Visakorpi, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-18210-3 · Cited by 59
Aurora kinase A mediates c‐Myc's oncogenic effects in hepatocellular carcinoma
Lu, L.-F., Han, H., Tian, Y., Li, W., Zhang, J., Feng, M., & Li, Y. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22223 · Cited by 58
“The over-expression of Aurka leads to tumor recurrence and therapeutic drug resistance [19,20].”
BackgroundGolgi complex fragmentation in G2/M transition: An organelle‐based cell‐cycle checkpoint
Corda, D., Barretta, M. L., Cervigni, R. I., & Colanzi, A. (2012) · IUBMB Life · doi:10.1002/iub.1054 · Cited by 56
Ramani, P., Nash, R. L., Sowa‐Avugrah, E., & Rogers, C. A. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1900-4 · Cited by 55
“Targeting key components of the mitotic machinery, such as Aurora kinase A (AURKA), Aurora kinase B (AURKB), and polo-like kinase 1 (PLK1) [9, 10], represents a promising strategy in cancer therapy in NBs [11–13].”
BackgroundCilia and cilia-associated proteins in cancer
Seeger‐Nukpezah, T., Little, J. L., Serzhanova, V., & Golemis, E. A. (2013) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2013.03.004 · Cited by 55
“For instance, AURKA overexpression or gene amplification is associated with malignancies of breast, colon, pancreas, ovarian, bladder, liver, and gastric origins; extensive interplay between AURKA and PLK1 in cancer has led each to be heavily investigated as drug targets (reviewed in [19,20]).”
BackgroundSENP1 and SENP2 affect spatial and temporal control of sumoylation in mitosis
Cubeñas-Potts, C., Goeres, J., & Matunis, M. J. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-05-0230 · Cited by 59
“Phosphorylation has been particularly well studied, as some of the bestcharacterized regulators of kinetochore and microtubule interactions possess protein kinase activity, including the Aurora kinases and BUBR1 (Lens et al., 2010; Bolanos-Garcia and Blundell, 2011).”
BackgroundMolecular insight into the regulation and function of MCAK
Ritter, A., Kreis, N., Louwen, F., Wordeman, L. G., & Yuan, J. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2016.1178705 · Cited by 64
“…its coactivator BORA or TPX2 (Eyers et al., 2003; Hutterer et al., 2006) enables Aurora A to regulate the mitotic entry, centrosome maturation and separation, bipolar spindle assembly and chromosome alignment on the metaphase plate (Barr & Gergely, 2007; Lens et al., 2010; Marumoto et al., 2005).”
BackgroundFunctionality of the chromosomal passenger complex in cancer
Hindriksen, S., Meppelink, A., & Lens, S. M. A. (2015) · Biochemical Society Transactions · doi:10.1042/bst20140275 · Cited by 56
Self-citationMolecular Regulation of the Spindle Assembly Checkpoint by Kinases and Phosphatases
Manic, G., Corradi, F., Sistigu, A., Siteni, S., & Vitale, I. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.08.004 · Cited by 65
Aberrantly expressed AURKC enhances the transformation and tumourigenicity of epithelial cells
Tsou, J., Chang, K., Chang‐Liao, P., Yang, S., Lee, C., Chen, Y., Lee, Y., Lin, B., Lee, J., Shen, M., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2934 · Cited by 58
Wang, X., Zhang, L., Zhao, F., Xu, R., Jiang, J., Zhang, C., Liu, H., & Huang, H. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3315-8 · Cited by 54
Mitotic arrest and slippage induced by pharmacological inhibition of Polo‐like kinase 1
Raab, M., Krämer, A., Hehlgans, S., Sanhaji, M., Kurunci‐Csacsko, E., Dötsch, C., Bug, G., Ottmann, O. G., Becker, S., Pachl, F., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.020 · Cited by 53
Zheng, X., Chi, J., Zhi, J., Zhang, H., Yue, D., Zhao, J., Li, D., Li, Y., Gao, M., & Guo, J. (2017) · Oncogene · doi:10.1038/onc.2017.354 · Cited by 51
Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Hatzimichael, E. C., Georgiou, G. K., Benetatos, L., & Briasoulis, E. C. (2013) · Europe PMC (PubMed Central) · Cited by 64
FBXW7 is involved in Aurora B degradation
Teng, C. J., Hsieh, Y.-C., Phan, L. M., Shin, J., Gully, C., Velázquez-Torres, G., Skerl, S., Yeung, S. J., Hsu, S., & Lee, M. (2012) · Cell Cycle · doi:10.4161/cc.22381 · Cited by 58
Sadaie, M., Dillon, C., Narita, M., Young, A. R. J., Cairney, C. J., Godwin, L. S., Torrance, C. J., Bennett, D. C., Keith, W. N., & Narita, M. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-01-0003 · Cited by 57
“Inhibition of AURKB in cell culture leads to a failure to biorient chromosomes and perturbed cytokinesis and, as a consequence, causes polyploidization and an eventual loss of viability (Ditchfield et al., 2003; Kaestner et al., 2009; Lens et al., 2010).”
BackgroundDiscovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)
Nie, Z., Feher, V. A., Natala, S. R., McBride, C. M., Kiryanov, A. A., Jones, B., Lam, B., Liu, Y., Kaldor, S. W., Stafford, J. A., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.083 · Cited by 50
Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function
Betts, B., Veerapathran, A., Pidala, J., Yang, H., Horna, P., Walton, K., Cubitt, C., Gunawan, S., Lawrence, H., Lawrence, N., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8269 · Cited by 47
“Aurora kinase isoforms ubiquitously regulatemitotic progression and cellular polarity in human cells (12, 13) but also mediate T cell costimulation (6).”
BackgroundWu, J.-M., Chen, C.-T., Coumar, M. S., Lin, W., Chen, Z.-J., Hsu, J. T.-A., Peng, Y.-H., Shiao, H., Lin, W., Chu, C.-Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220523110 · Cited by 51
“T overexpression of Aurora kinases is closely associated with tumorigenesis (1, 2).”
BackgroundToward personalized cancer nanomedicine – past, present, and future
Stegh, A. H. (2012) · Integrative Biology · doi:10.1039/c2ib20104f · Cited by 55
Hengeveld, R. C. C., Hertz, N. T., Vromans, M. J. M., Zhang, C., Burlingame, A. L., Shokat, K. M., & Lens, S. M. A. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.013912 · Cited by 49
“In particular, the presence of two other Aurora kinases (A and C) with a high degree of homology to Aurora B makes it particularly challenging to identify small molecules that selectively inhibit Aurora B (5).”
BackgroundSelf-citationLiu, X., Zheng, H., Li, X., Wang, S., Meyerson, H. J., Yang, W., Neel, B. G., & Qu, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508535113 · Cited by 55
“This dynamic localization pattern of Shp2 is remarkably similar to those of Aurora B and Plk1, two serine/ threonine kinases that play critical roles in mitosis and cytokinesis (26, 27).”
BackgroundTakeshita, T., Asaoka, M., Katsuta, E., Photiadis, S. J., Narayanan, S., Yan, L., & Takabe, K. (2019) · Europe PMC (PubMed Central) · Cited by 54
Rajput, A. B., Hu, N., Varma, S., Chen, C., Ding, K., Park, P. C., Chapman, J.-A. W., Sengupta, S., Madarnas, Y., Elliott, B. E., et al. (2011) · Cancers · doi:10.3390/cancers3044212 · Cited by 50
“Ongoing clinical trials are investigating new anti-mitotic drugs targeting non-microtubule structures, such as mitotic kinesins and Aurora or polo-like kinases [29-33].”
BackgroundAl-Sanea, M. M., Elkamhawy, A., Paik, S., Lee, K., Kerdawy, A. M. E., Abbas, B. S. N., Roh, E. J., Eldehna, W. M., Elshemy, H. A. H., Bakr, R. B., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115525 · Cited by 48
Asteriti, I. A., Cesare, E. D., Mattia, F. D., Hilsenstein, V., Neumann, B., Cundari, E., Lavia, P., & Guarguaglini, G. (2014) · Oncotarget · doi:10.18632/oncotarget.2190 · Cited by 52
“As other mitotic regulators, Aurora kinases are often abnormally expressed in tumor cells and are being investigated as targets of anti-mitotic compounds for cancer therapy [9, 10].”
Jang, M.-S., Lee, S.-J., Kang, N. S., & Kim, E. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0760 · Cited by 48
“Moreover, enhanced kinase activity associatedwith Plk1 and Aur-A overexpression confers a proliferative advantage in some tumors (11).”
Seeger‐Nukpezah, T., Liebau, M. C., Höpker, K., Lamkemeyer, T., Benzing, T. R., Golemis, E. A., & Schermer, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038838 · Cited by 54
Li, J., Ma, W., Wang, P.-Y., Hurley, P. J., Bunz, F., & Hwang, P. M. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.05.022 · Cited by 48
“Using a kinase substrate screening assay, we identified the Ser-137 amino acid residue of PLK1 (PLK1-S137), the prototypical PLK family member involved in progression of mitosis, as a target of PLK2 kinase activity and showed that PLK1-S137 phosphorylation promotes the survival of cells under oxidative stress [4, 7, 8…”
MethodRegulation of the centrosome cycle
Fujita, H., Yoshino, Y., & Chiba, N. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1075643 · Cited by 51
The p38 MAPK inhibitor BIRB796 enhances the antitumor effects of VX680 in cervical cancer
Jin, X., Mo, Q., Zhang, Y., Gao, Y., Wu, Y., Li, J., Hao, X., Ma, D., Gao, Q., & Chen, P. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1177676 · Cited by 47
“Aurora B kinase coordinates with BUB1, BUB3, MAD2, MAD1 and BUBR1 to form the spindle assembly checkpoint (SAC) complex and hence regulates the G2/M transition during cell cycle progression.(19)”
BackgroundPhadke, M. S., Sini, P., & Smalley, K. S. M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0832 · Cited by 47
“Aurora kinase A plays a major role in centrosome function and spindle assembly as well as cytokinesis and the telophase of mitosis (17).”
Mastl kinase, a promising therapeutic target, promotes cancer recurrence
Wang, L., Luong, V. Q., Giannini, P. J., & Peng, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2565 · Cited by 52
“To date, a number of small molecule inhibitors of Plk1 and Aurora kinases are under clinical development for cancer therapy [3].”
BackgroundYu, X., Liang, Q., Liu, W., Zhou, L. Q., Li, W., & Liu, H. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.10.030 · Cited by 46
“Aurora B is overexpressed in many tumor types and has been linked to poor patient prognosis in cancers (Lens et al., 2010; Otto and Sicinski, 2017).”
BackgroundThe FOXM1-PLK1 axis is commonly upregulated in oesophageal adenocarcinoma
Dibb, M. J., Han, N., Choudhury, J., Hayes, S. J., Valentine, H. R., West, C., Ang, Y. S., & Sharrocks, A. D. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.424 · Cited by 45
“Similarly, its target gene PLK1 is also expressed under these conditions across many cell types (reviewed in Lens et al, 2010).”
BackgroundMethodInfluentialJürgensmeier, J. M., Eder, J. P., & Herbst, R. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0753 · Cited by 47
Cheng, L., Ke, Y., Yu, S., & Jing, J. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s115364 · Cited by 45
Kinases Involved in Both Autophagy and Mitosis
Li, Z., & Zhang, X. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091884 · Cited by 45
“Long-term PLK1 inhibition by its inhibitors, such as BI2536, arrests cells in prometaphase and thus PLK1 inhibitors are investigated as antimitotic agents for cancer treatment considering its high expression in tumors [45,46].”
BackgroundOncogenic MYC amplifies mitotic perturbations
Littler, S., Sloss, O., Geary, B., Pierce, A., Whetton, A. D., & Taylor, S. S. (2019) · Open Biology · doi:10.1098/rsob.190136 · Cited by 45
“PLK1 regulates multiple cell cycle processes, including DNA replication, recovery from G2 checkpoint arrest, entry into mitosis, centrosome maturation, bipolar spindle formation, kinetochore–microtubule attachment, activation of the anaphase promoting complex/cyclosome, resolution of sister chromatid cohesion and cyto…”
BackgroundGeuns-Meyer, S. D., Cee, V. J., Deak, H. L., Du, B., Hodous, B. L., Nguyen, H. N., Olivieri, P. R., Schenkel, L. B., Vaida, K. R., Andrews, P., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00183 · Cited by 46
Solc, P., Baran, V., Mayer, A., Böhmová, T. (., Panenková, G. (., Šašková, A., Schultz, R. M., & Motlík, J. (2012) · Biology of Reproduction · doi:10.1095/biolreprod.112.101014 · Cited by 45
“AURKA activity is essential for G2 checkpoint recovery following DNA-damage induced G2 arrest [10, 14, 15].”
InfluentialHatfield, K. J., Reikvam, H., & Bruserud, Ø. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.957671 · Cited by 47
“Several of the identified genes also show high expression in other human malignancies [27,28,42-45].”
BackgroundMeehan, M., Parthasarathi, L., Moran, N. M., Jefferies, C. A., Foley, N. H., Lazzari, E., Murphy, D. B., Ryan, J., Ortiz, B., Fabius, A. W. M., et al. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-6 · Cited by 43
“NEK2 is an integral component of the mitotic spindle-assembly checkpoint which is necessary for proper chromosome segregation during metaphase-anaphase transition [27], while PLK1 is an early trigger for G2/M transition [28].”
BackgroundThe Dawn of Aurora Kinase Research: From Fly Genetics to the Clinic
Carmena, M., Earnshaw, W. C., & Glover, D. M. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00073 · Cited by 43
Aurora A, MCAK, and Kif18b promote Eg5-independent spindle formation
van Heesbeen, R. G. H. P., Raaijmakers, J. A., Tanenbaum, M. E., Halim, V. A., Lelieveld, D., Lieftink, C., Heck, A. J. R., Egan, D. A., & Medema, R. H. (2016) · Chromosoma · doi:10.1007/s00412-016-0607-4 · Cited by 48
“Despite the fact that a wide variety of Aurora A substrates have been identified (Lens et al. 2010; Hochegger et al. 2013), clear downstream targets involved in centrosome separation and bipolar spindle assembly are poorly understood.”
BackgroundSelf-citationPolo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions
Bahassi, E. M. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011011 · Cited by 50
Bhullar, K. S., Jha, A., & Rupasinghe, H. P. V. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.09.020 · Cited by 46
Li, L., Xue, W., Shen, Z., Liu, J., Hu, M., Cheng, Z., Wang, Y., Chen, Y., Chang, H., Liu, Y., et al. (2020) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2020.06.013 · Cited by 40
“The polo-like kinase (PLK) family members are serine/threonine protein kinases, which regulate many steps of the cell cycle.(6) This family has five members: PLK1, PLK2, PLK3, PLK4, and PLK5.”
BackgroundHorwacik, I., Durbas, M., Boratyn, E., Węgrzyn, P., & Rokita, H. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.018 · Cited by 41
Winter, G. E., Rix, U., Lissat, A., Stukalov, A., Müllner, M. K., Bennett, K. L., Colinge, J., Nijman, S. M. B., Kubicek, S., Kovar, H., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0100 · Cited by 43
“Aurora kinases A and B are serine/threonine kinases that play critical roles in mitosis (44).”
BackgroundChen, Q., Zhang, M., Pan, X., Yuan, X., Zhou, L., Yan, L., Zeng, L., Xu, J., Yang, B., Zhang, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109740 · Cited by 43
Velásquez, Z. D., Conejeros, I., Larrazabal, C., Kerner, K., Hermosilla, C. R., & Taubert, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-48961-0 · Cited by 42
Regulatory mechanisms that control mitotic kinesins
Yount, A. L., Zong, H., & Walczak, C. E. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.12.015 · Cited by 39
“In addition, some kinases and phosphatases simultaneously hit the same kinesins to tune the balance between phosphorylation and dephosphorylation to modulate activity or spindle targeting [56, 57].”
BackgroundRegulation of polo-like kinase 1 by DNA damage and PP2A/B55α
Wang, L., Guo, Q., Fisher, L. A., Liu, D., & Peng, A. (2014) · Cell Cycle · doi:10.4161/15384101.2014.986392 · Cited by 41
“Interestingly, in addition to regulation of cell division, Plk1 has also been shown to govern the cellular DNA damage response (DDR), an essential surveillance mechanism that prevents genomic instability and maintains cell homeostasis.(5,8) As DNA damage is frequently induced by both endogenous and exogenous agents, a…”
BackgroundTargeting of Fzr/Cdh1 for timely activation of the APC/C at the centrosome during mitotic exit
Meghini, F., Martins, T., Tait, X., Fujimitsu, K., Yamano, H., Glover, D. M., & Kimata, Y. (2016) · Nature Communications · doi:10.1038/ncomms12607 · Cited by 43
Cyclers’ kinases in cell division: from molecules to cancer therapy
Milletti, G., Colicchia, V., & Cecconi, F. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01196-z · Cited by 39
Neise, D., Sohn, D., Stefanski, A., Goto, H., Inagaki, M., Wesselborg, S., Budach, W., Stühler, K., & Jänicke, R. U. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.386 · Cited by 38
Metadata
- Authors
- Lens, S. M. A., Voest, E. E., & Medema, R. H.
- Affiliations
- University Medical Center Utrecht (NL)
- Corresponding author
- Lens, Susanne M. A.
- Medema, René H.
- Venue
- Nature Reviews Cancer
- Published
- 2010-11-24
- Volume
- 10
- Issue
- 12
- Pages
- 825-841
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1994488152
- Cited by
- 597
- References
- 227
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 10 · 2023: 28 · 2022: 24 · 2021: 29 · 2020: 42 · 2019: 37 · 2018: 27 · 2017: 33 · 2016: 36 · 2015: 56 · 2014: 59 · 2013: 64 · 2012: 65
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- Polo-like kinase, Aurora kinases, PLK1, AURKA, Aurora B kinase, mitosis, kinase inhibitors, anticancer agents, off-target effects, chemosensitization, targeted therapy
- MeSH terms
- Polo-Like Kinase 1, Animals, Chromatids, Humans, Mitosis, Neoplasms, Proto-Oncogene Proteins, Protein Serine-Threonine Kinases, Kinetochores, Cell Cycle Proteins, Protein Kinase Inhibitors, Cytokinesis, Aurora Kinase A, Aurora Kinase B, Aurora Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.